ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.034,63
1,36%
S&P 500
5.770,20
0,55%
US Dollar vs BRL
5,7879
0,00%
Bitcoin
84.433,22
-1,99%
Brent Oil
70,235
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) Notícias

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KZIA
DataHoraFonteTítuloCódigoCompanhia
21/02/202508:33Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
20/02/202518:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
20/02/202510:46PR Newswire (US)Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's DiseaseNASDAQ:KZIAKazia Therapeutics Ltd
06/02/202502:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
30/01/202518:31Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
30/01/202509:30PR Newswire (US)Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerNASDAQ:KZIAKazia Therapeutics Ltd
17/01/202518:30Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
16/01/202512:40Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
14/01/202518:00PR Newswire (US)Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
13/01/202510:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
10/01/202511:58PR Newswire (US)Kazia Therapeutics Announces $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
31/12/202410:00PR Newswire (US)Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDANASDAQ:KZIAKazia Therapeutics Ltd
11/12/202410:00PR Newswire (US)Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
27/11/202418:30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:KZIAKazia Therapeutics Ltd
15/11/202418:02Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:KZIAKazia Therapeutics Ltd
14/11/202418:19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
06/11/202421:53Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
04/11/202409:30PR Newswire (US)Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma MultiformeNASDAQ:KZIAKazia Therapeutics Ltd
01/11/202417:05Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:KZIAKazia Therapeutics Ltd
24/10/202409:22Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
02/10/202409:45PR Newswire (US)Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society foNASDAQ:KZIAKazia Therapeutics Ltd
23/09/202409:30PR Newswire (US)Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
12/09/202408:30PR Newswire (US)KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERNASDAQ:KZIAKazia Therapeutics Ltd
10/07/202411:35AllPennyStocks.comBiotech Experiences Strong Open Following Major AnnouncementNASDAQ:KZIAKazia Therapeutics Ltd
10/07/202408:30PR Newswire (US)Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaNASDAQ:KZIAKazia Therapeutics Ltd
27/06/202409:15PR Newswire (US)KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERNASDAQ:KZIAKazia Therapeutics Ltd
23/05/202415:41PR Newswire (US)Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementNASDAQ:KZIAKazia Therapeutics Ltd
01/05/202409:45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
21/03/202409:52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
13/03/202409:00PR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:KZIA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
UNIP6
UNIPAR PNB
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios